Catalyst
Slingshot members are tracking this event:
GlaxoSmithKline (GSK) files EU regulatory submission for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GSK |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 02, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Chronic Obstructive Pulmonary Disease, Fluticasone Furoate/umeclidinium/vilanterol
